Lori Hu - 16 Jun 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Reporting relationship: Director
Issuer ticker: ELEV
Reported as of: 16 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2023, 16:13:52 UTC
Prior SEC filing: 22 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Robert Yang, Attorney-in-Fact

Key filing fact

Lori Hu filed Form 4 for Elevation Oncology, Inc. (ELEV) on 21 Jun 2023.

Key facts

This page summarizes Lori Hu's Form 4 filing for Elevation Oncology, Inc. (ELEV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2023, 16:13.

Change

Previous filing in this sequence was filed on 22 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELEV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +31,238
Change %
Price: $0.000000
Shares after: 31,238
Date: 16 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,238
Exercise price: $1.47
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney